Price & Value of Cancer Drug

Cost of one month of treatment for an adult for each new cancer drug approved by the United States Food and Drug Administration, based on Medicare reimbursement rates and by year of drug approval.


Comparative Cancer Drug Pricing
Learn more


Download Power Point slide versions of these graphs. You may use these slides in your presentations.

Download a PDF of the drug prices. The PDF includes generic name, brand name, year of FDA approval, monthly cost (actual $’s), monthly cost (2014 $’s).

Download a PDF explaining the methods used for drug pricing calculations.

Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med. 2009 Feb 5;360(6):626-33.

Editorials on Drug Costs

Forbes: Cancer: Unpronounceable Drugs, Incomprehensible Prices

Forbes: Cancer: Could High Drug Prices Be Bad For Innovation?

Forbes: Debate: Do High Drug Prices Drive Innovation, Or Hurt It?

The New England Journal of Medicine: Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer (Letter to the Editor)

The Lancet: Targeted Drugs for Metastatic Renal Cell Carcinoma

The New England Journal of Medicine: The Price Tag on Progress — Chemotherapy for Colorectal Cancer

The Journal of Clinical Oncology: Th e Just Price of Cancer Drugs and the Growing Cost of Cancer Care: Oncologists Need to Be Part of the Solution

Drug Price Reform and Policy Analysis

Journal of Economic Perspectives: Pricing in the Market for Anticancer Drugs

Health Affairs: The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities

The Journal of the American Medical Association: Cost Consequences of the 340B Drug Discount Program

The New York Times: In Cancer Care, Cost Matters

Health Affairs: How Medicare Could Use Comparative Effectiveness Research In Deciding On New Coverage And Reimbursement

The Journal of the American Medical Association: Reforming the Payment System for Medical Oncology

The Journal of the American Medical Association: Indication-Specific Pricing for Cancer Drugs

Journal of Clinical Oncology: Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists